I85PREP
⌘ K
NPC B.Pharm study materials
NPC B.Pharm study resources

NPC B.Pharm: Regulations and Guidelines: Registration, GMP and Post-Marketing Control

NPC B.Pharm · Work through your exam, one topic at a time.

All guide sections

Regulations and Guidelines: Registration, GMP and Post-Marketing Control

This domain covers the subordinate instruments that translate the Acts into practice: DDA drug registration guidelines, GMP/GDP requirements, labeling and advertising rules, pharmacovigilance and clinical-trial guidance, and national treatment tools such as the National List of Essential Medicines and Standard Treatment Guidelines. The exam tests which instrument governs a given activity and what evidence a dossier must contain.

Registration and manufacturing

  • Product registration requires an application with quality, safety and efficacy data, proposed labeling, manufacturing-site GMP evidence and, where required, bioequivalence data.
  • GMP guidance covers premises, personnel, documentation, validation, complaints and recalls; GDP covers storage and distribution, including cold chain.
  • Labels must be legible, in the required language(s), and include the approved name, strength, batch, expiry, storage and manufacturer.

Post-marketing and clinical use

  • Pharmacovigilance guidance requires ADR reporting to the national centre; serious reactions are expedited.
  • Clinical trials need ethical and regulatory approval before enrolment.
  • Essential-medicines and standard-treatment guidance inform public-sector procurement and rational prescribing but do not replace legal prescribing restrictions.

Worked example

A company seeks approval for a new oral antihypertensive. Reasoning: file a registration application with DDA; supply chemical, pharmaceutical and biological data; provide GMP evidence for the site; propose a label meeting local language and storage requirements; check whether a bioequivalence study is needed against the comparator; only after registration may it import or market. A foreign approval certificate supports but does not replace local review.

Traps

Treating foreign approval as automatic Nepali approval; submitting a dossier without site GMP evidence; ignoring local-language labeling; assuming an essential-medicines listing is a marketing authorisation; confusing GMP (manufacture) with GDP (distribution).